Search

Displaying results 5301 - 5310 of 5498 in total
  1. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    [L42725] It is advantageous over currently available management therapies for PKU, such as [DB00360], that are ineffective to many patients due to long-term adherence issues or inadequate Phe-lowering

  2. Drug

    Laromustine

    go.drugbank.com/drugs/DB05817
    Investigational

    VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.

  3. Drug

    Acetylcysteine zidrimer

    go.drugbank.com/drugs/DB16496
    Investigational

  4. Drug

    Cambinol

    go.drugbank.com/drugs/DB15493
    Experimental

    Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.

  5. Drug

    Patupilone

    go.drugbank.com/drugs/DB03010
    Investigational

    Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.

  6. Drug

    Tozinameran

    go.drugbank.com/drugs/DB15696
    ApprovedInvestigational

    It is designed to induce immunity against SARS-CoV-2, the virus responsible for causing COVID-19.

  7. Drug

    Ohmefentanyl

    go.drugbank.com/drugs/DB01570
    ExperimentalIllicit

    Ohmefentanyl has three stereogenic centers and hence, it can derive into eight stereoisomers, currently named F9201–F9208.

  8. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

  9. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039.

  10. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    TM5614 inhibition of PAI-1, specifically, downregulates PCSK9 at the transcriptional level[A228793].